AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 73.85% | -11.76% | 5.97% | -12.34% | 27.44% |
| Total Depreciation and Amortization | 143.76% | -81.10% | -81.44% | -2.38% | -298.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -57.49% | 249.17% | 152.37% | -11.07% | 72.78% |
| Change in Net Operating Assets | -410.17% | -216.58% | -109.10% | 138.78% | 957.56% |
| Cash from Operations | -334.29% | -82.10% | -8.14% | 72.30% | 59.21% |
| Capital Expenditure | 37.02% | 51.78% | 33.54% | 55.94% | -8.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 65.55% | 104.45% | -125.55% | -65.64% | 618.93% |
| Cash from Investing | 110.45% | 886.70% | -161.06% | -73.47% | 246.79% |
| Total Debt Issued | 143.67% | 126.91% | 94.25% | 103.85% | -14.14% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,520.90% | 1.09% | -4,752.46% | 3.78% | 4.32% |
| Cash from Financing | -0.65% | 134.40% | -227.31% | 110.88% | 10.01% |
| Foreign Exchange rate Adjustments | 113.43% | -248.23% | 1,869.77% | 175.54% | -302.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 50.92% | 57.19% | -370.13% | 130.17% | 175.92% |